Onco-nephrology: an Appraisal of the Cancer and Chronic Kidney Disease Links

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2015 Feb 5

PMID 25648910

Citations 14

Authors

Hassan Izzedine

Mark A Perazella

Affiliations

Soon will be listed here.

Abstract

A bidirectional relationship has been observed for kidney disease and cancer. On the one hand, cancer is an important complication noted in kidney disease as well as a major cause of morbidity and mortality in this group. On the other hand, improved cancer treatment has prolonged survival, but also increased the development of acute and chronic kidney disease. The combination of cancer and kidney disease makes it challenging for clinicians to provide comprehensive and safe therapies for this group of patients. As such, clinicians caring for this group must develop expertise and become competent in the practice of a newly evolving subspecialty of nephrology known as 'onco-nephrology'. This brief narrative review will focus on the cancer risk in patients with underlying kidney disease, the therapies such as erythropoiesis-stimulating agents on cancer progression and other outcomes, and the appropriate dosing of anti-cancer agents in patients with underlying kidney disease.

Citing Articles

Multiple metabolic analysis of [F]FDG PET/CT in patients with kidney disease.

Jiao H, Qiu Y, Chen Z, Zhang Y, Huang W, Yang Q Heliyon. 2025; 11(4):e42522.

PMID: 40028531 PMC: 11870161. DOI: 10.1016/j.heliyon.2025.e42522.

Renal involvement in solid cancers: epidemiological, clinical and histological characteristics study of 154 onconephrology patients.

Gueutin V, Cardineau A, Mathian A, Lanot A, Comoz F, Brocheriou I BMC Nephrol. 2024; 25(1):367.

PMID: 39427142 PMC: 11490999. DOI: 10.1186/s12882-024-03812-7.

Albuminuria and the risk of cancer: the Stockholm CREAtinine Measurements (SCREAM) project.

Luo L, Yang Y, Kieneker L, Janse R, Bosi A, Mazhar F Clin Kidney J. 2023; 16(12):2437-2446.

PMID: 38046028 PMC: 10689191. DOI: 10.1093/ckj/sfad145.

Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease.

Zhang W, Liu L, Xiao X, Zhou H, Peng Z, Wang W Front Immunol. 2023; 14:961642.

PMID: 37026010 PMC: 10070855. DOI: 10.3389/fimmu.2023.961642.

Onco-nephrology: Physicians' Expectations About a New Subspecialty.

Delaye M, Try M, Rousseau A, Lafargue M, Saillant A, Bainaud M J Cancer Educ. 2022; 38(3):878-884.

PMID: 35840858 DOI: 10.1007/s13187-022-02201-8.

References

Aapro M, Link H . September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008; 13 Suppl 3:33-6. DOI: 10.1634/theoncologist.13-S3-33. View

Leyland-Jones B . Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003; 4(8):459-60. DOI: 10.1016/s1470-2045(03)01163-x. View

Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G . Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23(25):5960-72. DOI: 10.1200/JCO.2005.06.150. View

Stohlawetz P, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler H . Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000; 95(9):2983-9. View

Ait-Oudhia S, Scherrmann J, Krzyzanski W . Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J Pharmacol Exp Ther. 2010; 334(3):897-910. PMC: 2939674. DOI: 10.1124/jpet.110.167304. View

Gekle M, Knaus P, Nielsen R, Mildenberger S, Freudinger R, Wohlfarth V . Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol. 2003; 552(Pt 2):471-81. PMC: 2343374. DOI: 10.1113/jphysiol.2003.048074. View

Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B . Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89(7):1221-7. PMC: 2394311. DOI: 10.1038/sj.bjc.6601219. View

Yeung C, Shen D, Thummel K, Himmelfarb J . Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2013; 85(3):522-8. PMC: 4276411. DOI: 10.1038/ki.2013.399. View

Ma M, Lim W, Turner R, Chapman J, Craig J, Wong G . The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis. Transplantation. 2014; 98(12):1286-93. DOI: 10.1097/TP.0000000000000375. View

10.

Caro J, Salas M, Ward A, Goss G . Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91(12):2214-21. View

11.

Perazella M, Markowitz G . Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010; 6(8):461-70. DOI: 10.1038/nrneph.2010.71. View

12.

Weng P, Hung K, Huang H, Chen J, Sung P, Huang K . Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol. 2011; 6(5):1121-8. PMC: 3087779. DOI: 10.2215/CJN.09011010. View

13.

Birkeland S, Lokkegaard H, Storm H . Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000; 355(9218):1886-7. DOI: 10.1016/s0140-6736(00)02298-4. View

14.

Fried L, Katz R, Sarnak M, Shlipak M, Chaves P, Jenny N . Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005; 16(12):3728-35. DOI: 10.1681/ASN.2005040384. View

15.

Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume M, Lloyd A . Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009; 180(11):E62-71. PMC: 2683210. DOI: 10.1503/cmaj.090470. View

16.

Kiberd B, Rose C, Gill J . Cancer mortality in kidney transplantation. Am J Transplant. 2009; 9(8):1868-75. DOI: 10.1111/j.1600-6143.2009.02728.x. View

17.

Thomas G, Ali S, Hoebers F, Darcy K, Rodgers W, Patel M . Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2007; 108(2):317-25. PMC: 2350198. DOI: 10.1016/j.ygyno.2007.10.011. View

18.

Pfeffer M, Burdmann E, Chen C, Cooper M, de Zeeuw D, Eckardt K . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21):2019-32. DOI: 10.1056/NEJMoa0907845. View

19.

Yonemura Y, Kawakita M, Fujimoto K, Sakaguchi M, Kusuyama T, Hirose J . Effects of short-term administration of recombinant human erythropoietin on rat megakaryopoiesis. Int J Cell Cloning. 1992; 10(1):18-27. DOI: 10.1002/stem.5530100105. View

20.

Christensson A, Savage C, Sjoberg D, Cronin A, OBrien M, Lowrance W . Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer. 2013; 133(6):1452-8. PMC: 3707943. DOI: 10.1002/ijc.28144. View